ClinicalTrials.gg
CompletedNCT05526222Updated Nov 3, 2026

A Phase III Study of Jaktinib in Adults With Moderate and Severe Atopic Dermatitis

A Phase 3 interventional study of Jaktinib Hydrochloride Tablet in Atopic Dermatitis, sponsored by Suzhou Zelgen Biopharmaceuticals Co.,Ltd. Completed at 2 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Phase 3, Interventional, and Treatment

Updated Nov 3, 2026Now CompletedPrimary completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
443
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 207 studies in Dermatitis, Atopic with a site in China — 65 open to participants now, 83 under way, 29 of them phase 3. Dermatitis, Atopic · China.

Enrollment
38th of 191
443 · median 163
Started
2022
with 21 others
Phase 3
60 of 207
21 open now
Registered
50th of 207
by date

Among the 207 studies in Dermatitis, Atopic with a site in China, this one is the 38th largest by enrollment of the 191 interventional ones that give a count, is one of 22 that started in 2022, is one of 60 in phase 3, and was the 50th registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

65 of the 207 studies in Dermatitis, Atopic with a site in China are open now. Recruiting first, the newest first:

60 more — sign in →

All 65 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 207 studies in Dermatitis, Atopic with a site in China, or all of them as a file.
02

Study summary

A multicenter, randomized, double-blind, placebo-controlled phase III clinical study of jaktinib hydrochloride tablets in the treatment of adult patients with moderate and severe atopic dermatitis

03

Conditions studied

  • Atopic Dermatitis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have fully understood the test and voluntarily signed the ;
  • When signing the informed consent form, the age of male or female subjects must be ≥ 18 years old;
  • The onset time of atopic dermatitis was at least 1 year at the time of screening, and the subjects met the Hanifin and Rajka criteria for atopic dermatitis at the time of screening;
  • For women with reproductive ability and all male subjects, during the trial period and within 6 months after the discontinuation of the trial drug, they must maintain abstinence or , including but not limited to physical and drug contraception.
  • The subjects were able to communicate well and agreed to follow the study and follow-up procedures.

Exclusion criteria

Exclusion Criteria:

  • The investigator considers that any subjects are not suitable to participate in the trial.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
443 participants (actual)

Study arms

  • Experimental
    Jaktinib low dose

    Low dose

    Drug: Jaktinib Hydrochloride Tablet

  • Experimental
    Jaktinib high dose

    High dose

    Drug: Jaktinib Hydrochloride Tablet

  • Placebo comparator
    Placebo

    Placebo

    Drug: Jaktinib Hydrochloride Tablet

Interventions

06

What researchers measure

Primary outcomes

  1. The efficacy in the treatment of moderate and severe atopic dermatitis

    The proportion of subjects whose Eczema Area and Severity Index (EASI) total score decreased by ≥ 75% from baseline

    Time frame: 16 weeks

  2. The efficacy in the treatment of moderate and severe atopic dermatitis

    The proportion of subjects with a systemic Investigator's Global Assessment (IGA) score of 0 or 1 and a decrease of ≥ 2 points from baseline

    Time frame: 16 weeks

Secondary outcomes

  1. The abnormal laboratory values and/or adverse events in the treatment of moderate and severe atopic dermatitis

    Number of Participants With Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment

    Time frame: up to 1 year

07

Study locations

2 sites
  • Peking University People's Hospital
    Beijing, Beijing Municipality 100044, China
  • Hospital for Skin Diseases, Institute of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College
    Nanjing, Jiangsu 210000, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2022 to primary completion in Aug 2025, 36 months.

Of 150 industry-sponsored phase 3 interventional studies under Dermatitis, Atopic, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 28. This study's 36 months is above that.

Counting every sponsor, half of 157 studies reached it within 18 months; a quarter within 13 and three quarters within 28.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 3, 2026: primary completion Jun 2026 → Aug 2025 and completion Sep 2026 → Aug 2025.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 25, 2022
First posted
Sep 2, 2022
StartActual
Jul 14, 2022
Primary completionActual
Aug 5, 2025was Jun 2026
CompletionActual
Aug 5, 2025was Sep 2026
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Nov 3, 2026
Sites
2 sites added, 1 site removed
Show 2 added (2 China)
  • Peking University People's Hospital · Beijing, China
  • Hospital for Skin Diseases, Institute of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College · Nanjing, China
Show 1 removed
  • 139 People's Middle Road · Changsha, China
Nov 3, 2026
Primary completion
Jun 2026→Aug 5, 2025 (actual)
Nov 3, 2026
Study completion
Sep 2026→Aug 5, 2025 (actual)
Nov 3, 2026
Show all 1 update
  1. Nov 3, 2026
    Active, not recruiting→Completed
    2 sites added, 1 site removed
    Show 2 added (2 China)
    • Peking University People's Hospital · Beijing, China
    • Hospital for Skin Diseases, Institute of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College · Nanjing, China
    Show 1 removed
    • 139 People's Middle Road · Changsha, China
    Primary completion Jun 2026→Aug 5, 2025 (now actual)
    Study completion Sep 2026→Aug 5, 2025 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05526222
Responsible party
Sponsor
First posted
Sep 2, 2022
Start date
Jul 14, 2022
Primary completion
Aug 5, 2025
Completion
Aug 5, 2025
Last update
Nov 3, 2026

Study contacts

Jason Wu
study director · Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Jaktinib

Start the discussion